3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Conditions
Primary Myelofibrosis
2
Myeloproliferative Disorders
2
Myelodysplastic Syndromes
2
Thrombocythemia, Essential
1
Recurrence
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Leukemia
1
Glioblastoma
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
ruxolitinib
7
fludarabine phosphate
3
bomedemstat
3
Whole-Body Irradiation
3
Tacrolimus
3
Specimen Handling
3
Mycophenolic Acid
3
Cyclophosphamide
3
Biopsy
3
fludarabine
2
Stem Cell Transplantation
2
Peripheral Blood Stem Cell Transplantation
2
Methotrexate
2
Melphalan
2
Injections
2
Busulfan
2
venetoclax
1
veliparib
1
piperine
1
pevonedistat
1
iadademstat
1
fedratinib
1
demethoxycurcumin
1
decitabine and cedazuridine drug combination
1
anagrelide
1
X-Rays
1
Valganciclovir
1
Transplantation
1
Topotecan
1
Therapeutics
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Thrombocythemia, Essential
×
INCB057643
×
1 year
×
Clear all
NCT04279847
2026-04-01
LIMBER
Incyte Corporation
Phase 1
Active not recruiting
140 enrolled